25 November 2021 - Novo Nordisk announced today that Health Canada has approved Wegovy (semaglutide injection), the first-and-only prescription weight-loss medication with once-weekly dosing. 

Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.

Wegovy is expected to be commercially available in Canada in the fall of 2022.

Read Novo Nordisk press release